指南与共识流行病学与生物统计基础与转化研究

关于精准糖尿病医学临床转化差距与机遇的第二份国际共识报告

Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine.
指南 / 共识 · Nat Med · 2023-10-05

该第二份精准糖尿病医学国际共识报告总结了针对单基因糖尿病、妊娠糖尿病、1型糖尿病和2型糖尿病四种类型,在预防、诊断、治疗、预后四大支柱领域的系统性证据综述结果。综述揭示了精准糖尿病医学可立即或近期临床实施的机遇,同时指出了知识差距,包括需要建立临床就绪度的共同标准并考虑成本效果、健康公平、预测准确性、责任和可及性,并概述了广泛临床实施的关键里程碑。

要点

  • 综述覆盖单基因、妊娠、1型和2型糖尿病的预防、诊断、治疗、预后四大领域。
  • 综述揭示了精准糖尿病医学可立即或近期临床实施的机遇。
  • 知识差距包括需建立临床就绪度共同标准,涵盖成本效果、健康公平、预测准确性、责任与可及性。

核心结论

  • 综述揭示了精准糖尿病医学可立即或近期临床实施的机遇,同时暴露了需获取新的临床相关证据的重要知识差距。
  • 知识差距包括需要建立临床就绪度的共同标准,涵盖成本效果、健康公平、预测准确性、责任和可及性的考量。
  • 报告概述了精准糖尿病医学广泛临床实施的关键里程碑。

研究设计与样本

  • 第二份精准糖尿病医学国际共识报告,总结了针对单基因糖尿病、妊娠糖尿病、1型糖尿病和2型糖尿病四种公认类型,在预防、诊断、治疗、预后四大精准医学支柱领域进行的系统性证据综述的结果。
  • 报告指出,由于该主题文献浩瀚,综述并不完整。

主要发现

  • 综述揭示了精准糖尿病医学可立即或近期临床实施的机遇。
  • 报告暴露了重要的知识差距,聚焦于需要获取新的临床相关证据。
  • 知识差距包括需要建立临床就绪度的共同标准,涵盖成本效果、健康公平、预测准确性、责任和可及性的考量。
  • 报告概述了精准糖尿病医学广泛临床实施的关键里程碑。

局限性

  • 报告指出,由于该主题文献浩瀚,综述并不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Precision medicine is part of the logical evolution of contemporary evidence-based medicine that seeks to reduce errors and optimize outcomes when making medical decisions and health recommendations. Diabetes affects hundreds of millions of people worldwide, many of whom will develop life-threatening complications and die prematurely. Precision medicine can potentially address this enormous problem by accounting for heterogeneity in the etiology, clinical presentation and pathogenesis of common forms of diabetes and risks of complications. This second international consensus report on precision diabetes medicine summarizes the findings from a systematic evidence review across the key pillars of precision medicine (prevention, diagnosis, treatment, prognosis) in four recognized forms of diabetes (monogenic, gestational, type 1, type 2). These reviews address key questions about the translation of precision medicine research into practice. Although not complete, owing to the vast literature on this topic, they revealed opportunities for the immediate or near-term clinical implementation of precision diabetes medicine; furthermore, we expose important gaps in knowledge, focusing on the need to obtain new clinically relevant evidence. Gaps include the need for common standards for clinical readiness, including consideration of cost-effectiveness, health equity, predictive accuracy, liability and accessibility. Key milestones are outlined for the broad clinical implementation of precision diabetes medicine.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Tobias DK, Merino J, Ahmad A, et al. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nat Med. 2023. PMID: 37794253. doi:10.1038/s41591-023-02502-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。